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Abstract 
Background: Among the different serotypes of Streptococcus pneumoniae, serotype 3 has received global attention. 
We report the fatal case of a 76-year-old Japanese man who had an invasive pneumococcal disease associated with 
pneumonia caused by serotype 3 S. pneumoniae.
Case presentation: The patient had a history of hypertension, laryngeal cancer, chronic obstructive pulmonary dis-
ease, and type 2 diabetes mellitus. Following a cerebral arteriovenous malformation hemorrhage, he underwent sur-
gery to remove the hematoma and began rehabilitation. On day 66 of hospitalization, he suddenly developed a fever, 
and coarse crackles and wheezes were heard in his right lung. A diagnosis of hospital-acquired aspiration pneumonia 
was made, and initial treatment with piperacillin/tazobactam was started. Teicoplanin was added after S. pneumoniae 
was isolated from the blood culture, however, the patient died 5 days later. The S. pneumoniae detected in the sputum 
smear was serotype 3, showed mucoid colonies and susceptibility to penicillins, cephalosporins, carbapenems, and 
levofloxacin, but resistance to erythromycin.
Conclusion: We experienced a fatal case of pneumonia caused by mucoid serotype 3 S. pneumoniae with a thick 
capsule. Serotype 3-associated pneumonia may develop a wider pulmonary infiltrative shadow, a prolonged thera-
peutic or hospitalization course, and a poor outcome. Careful observation and intervention are required, and the use 
of additional antibiotics or intravenous immunoglobulins should be considered in such cases. Pneumococcal immu-
nization is also an important public health measure to minimize the development of severe infections caused by 
serotype 3 strains.
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Background
More than 95 different antigenic serotypes of Streptococ-
cus pneumoniae are known. Owing to a thicker capsule, 
greater virulence, and higher mortality rate compared 
to other strains [1, 2], serotype 3 S. pneumoniae has 
received global attention. We report a case of invasive 
pneumococcal disease (IPD) associated with pneumo-
nia caused by serotype 3 S. pneumoniae, with a dramatic 
clinical course.
Case presentation
A 76-year-old Japanese man with a history of hyperten-
sion, laryngeal cancer, chronic obstructive pulmonary 
disease (COPD), and type 2 diabetes mellitus developed 
a cerebral arteriovenous malformation hemorrhage and 
was hospitalized at Aichi Medical University Hospital, 
Japan. His vaccination history was unknown. Case char-
acteristics and laboratory data on the first visit are sum-
marized in Table  1. Following surgery for removal of 
the hematoma, he began rehabilitation and was encour-
aged to engage in early postoperative ambulation. In 
March, 2015, on the 66th day of hospitalization, he 
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developed a sudden fever and exhibited a sharp decline 
in oxygenation.
At the onset of fever, the patient’s vital signs were as follows: 
body temperature, 37.8  °C; blood pressure, 84/41  mmHg; 
heart rate, 107/min; respiration rate, 30/min; and SpO2, 82% 
(room air). Blood gas analysis (room air) showed pH 7.538, 
pCO2 25.7 mmHg, pO2 47.6 mmHg, HCO3− 21.4 mmol/L, 
and lactate 38.9 mg/dL. His level of consciousness was I-2 on 
the Japan Coma Scale. Physical examination showed coarse 
crackles and wheezes in the right lung. Based on chest radi-
ography (Fig. 1) and computed tomography images (Fig. 2), 
hospital-acquired aspiration pneumonia was diagnosed.
Piperacillin/tazobactam 4.5  g was administered three 
times daily as initial treatment (Fig.  3). Streptococcus 
pneumoniae infection was suspected based on a rapid 
identification test using a sputum smear, and a strain of 
S. pneumoniae was isolated from the blood culture sam-
pled at the onset of fever. The patient was admitted to 
the intensive care unit and teicoplanin was added to his 
treatment regimen. However, his SpO2 and respiratory 
rate continued to be unstable. After 5 days of concomi-
tant teicoplanin administration, the patient died.
Streptococcus pneumoniae detected in the smear and 
the morphologic characteristics of the colonies on blood 
agar are shown in Fig. 4. The isolate was mucoid serotype 
strain 3, with a thick capsule. Antibiotic susceptibility to 
penicillins, cephalosporins, carbapenems, and levofloxa-
cin was good, with resistance observed only to a mac-
rolide (erythromycin) (Table 2).
Conclusions
Streptococcus pneumoniae is encapsulated, which is 
highly important for its virulence. In particular, sero-
type 3 strains are reported to be heavily encapsulated 
compared to other serotypes [1, 2], and tend to form 
mucoid colonies [3]. These features are related to its high 
virulence as they protect the bacteria from phagocyto-
sis, inhibit opsonization by complement, and allow it to 
escape the neutrophil extracellular traps.
Mucoid serotype 3 is the second most common iso-
late in adult IPD cases. It is reported to be more com-
mon in adults with pneumonia, sepsis, and empyema/
pleuritis, but not meningitis. In a previous study from 
Japan, among isolates from 43 adult fatal cases, serotype 




Body weight 67.4 kg
Body mass index 23.9 kg/m2
Hematological test




Red blood cell count 441 × 104/µL
Hemoglobin 13.1 g/dL









Blood urea nitrogen 20.3 mg/dL
Creatinine 1.01 mg/dL




Total bilirubin 0.14 mg/dL
Aspartate aminotransferase 57 IU/L
Alanine aminotransferase 31 IU/L
Alkaline phosphatase 427 IU/L
Lactate dehydrogenase 402 IU/L
γ-glutamyl transpeptidase 152 IU/L
Cholinesterase 123 IU/L
Creatine phosphokinase 31 IU/L
Albumin 2.5 g/dL
C-reactive protein 16.26 mg/dL
Procalcitonin 13.81 ng/mL
Fig. 1 Chest radiography (decubitus) image at the onset of fever
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3 has remained dominant without significant changes 
over time [4]. Community-acquired pneumonia caused 
by mucoid-type pneumococcus is reported to develop a 
wider infiltrative shadow, higher treatment failure rate, 
and a longer treatment period or hospitalization than the 
non-mucoid type [5].
The serotypes of the strains in children and adults are 
different. An increased prevalence of serotype 3 S. pneu-
moniae among children was reported in one region of 
Japan after introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7) [6]. National surveillance of 
pediatric patients after the 13-valent pneumococcal con-
jugate vaccine (PCV13) introduction in Japan showed 
that the prevalence rates of serotype 3 were 0.8% and 
8.5% in IPD and non-IPD patients, respectively, in 2014 
[7]. Serotype 3 was not dominant overall, and there was 
no significant difference in its prevalence rate between 
2012 (PCV7 era, 3.7%) and 2014 (PCV13 era, 3.8%).
Serotype 3 has been reported to be dominant among 
case isolates in adult pneumococcal pneumonia. The 
Adult Pneumonia Study Group-Japan investigated etio-
logic factors at four community-based hospitals in four 
prefectures from September 2011 through January 2013. 
Of 100 S. pneumoniae isolates, serotype 3 was the most 
dominant (22%), followed by serotypes 11A (10%) and 
19F (8%) [8]. In a report on the annual changes in the 
prevalence of each serotype in lower respiratory samples 
of adult pneumococcal pneumonia patients from 2011 
to 2013, serotype 3 was continuously isolated from 15% 
or more patients, while the frequency of serotypes 19F, 
23F, and 4 decreased annually [9]. Serotype 3 is one of 
the remaining dominant serotypes in other countries and 
appears to be more important in older adults on a global 
level [10]. It should be noted that the prevalence of sero-
type 3 has not decreased despite higher-valent vaccine 
introduction.
An outbreak of pneumococcal pneumonia caused by S. 
pneumoniae serotype 3 was reported in a nursing home 
unit at a local hospital in Kanagawa, Japan, in 2013 [11]. 
Among 31 residents, 27 (87%) had been vaccinated for 
influenza in the 2012–13 season, but only 2 (7%) among 
them had been immunized with the 23-valent polysac-
charide pneumococcal vaccine (PPSV23). In total, ten 
confirmed cases of pneumonia and 16 influenza-like ill-
ness (ILI) cases were identified. In the same period, 6 of 
28 (attack rate 21%) staff members presented with ILI, 
but none developed pneumonia. All six S. pneumoniae 
isolates showed identical pulsed-field gel electrophore-
sis patterns and were susceptible to penicillins, cepha-
losporins, carbapenems, and vancomycin, and were 
Fig. 2 Chest computed tomography images at the onset of fever
Fig. 3 Clinical course of the present case, diagnosed as an invasive 
pneumococcal disease with pneumonia. Asterisk denotes matrix-
assisted laser desorption/ionization-time of flight mass spectrometry
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resistant to erythromycin and clindamycin. All pneumo-
nia patients were hospitalized and none had been vac-
cinated with PPSV23. Shiramoto et al. reported that the 
immunogenicity of PCV13 and PPSV23, measured as 
opsonophagocytic activity titer, for serotype 3 were both 
lower than that for the other serotypes, suggesting lower 
vaccination efficacy [12]. Another study reported that the 
effectiveness of the PCV13 vaccine for serotype 3 was not 
significant [13]. Although we cannot conclude that the 
relatively poor efficacy of vaccination is the only reason 
for the dominance of serotype 3 after the introduction of 
the higher-valent vaccine, we should take into account 
the possible variability of immunogenicity depending on 
the serotype.
The Advisory Committee on Immunization Practices 
(ACIP) recommended in 2014 that all adults ≥65  years of 
age should receive PCV13, followed by PPSV23 [14, 15]. This 
2-step vaccination approach is intended to maximize the 
efficacy of pneumococcal vaccination. Initial PCV13 induces 
acquired T cell memory function, and wider serotype cover-
age is induced by the subsequent PPSV23 [16]. In Japan, both 
PPSV23 and PCV13 have been used in the elderly to prevent 
pneumococcal infections since the approval of extended use 
of PCV13 in June 2014. The national immunization pro-
gram launched in October 2014 for those aged ≥65  years 
only subsidized PPSV23 [17]. Widespread adoption of ACIP 
recommendations would potentially improve the efficacy of 
pneumococcal immunization.
Addressing the antibacterial susceptibility, Okade et al. 
reported that 100% of the 42 serotype 3 strains in their 
study cohort had penicillin binding protein gene (pbp) 
mutations and macrolide resistance genes [6]. Minimum 
inhibitory concentrations (MICs) of penicillins are still 
usually low, even with the pbp mutations. The S. pneu-
moniae isolate in the present case was susceptible to 
penicillins, but resistant to a macrolide (erythromycin). 
However, the in  vivo–in vitro paradox of macrolides 
has recently been reported. For example, many azithro-
mycin-resistant pneumococcal pneumonia cases have 
successfully been treated using azithromycin alone [18]. 
A case of severe community-acquired pneumonia due 
to mucoid S. pneumoniae, that was macrolide-resistant 
and penicillin-susceptible, was also cured by additional 
azithromycin administration [16]. Based on the antibi-
otic susceptibility pattern of S. pneumoniae, penicillins 
are the first treatment choices for infections caused by 
serotype 3 strains. Macrolides can be considered for con-
comitant administration in cases in where penicillins do 
not show sufficient efficacy.
Fig. 4 Sputum smear (a) and colonies (b) of the isolate from the patient showing serotype 3 Streptococcus pneumoniae. Capsule is stained pale pink 
(a). Mucoid colonies on blood agar are not dimpled (b)
Table 2 Antibiotic susceptibility of the isolated Streptococ-
cus pneumoniae
a Minimum inhibitory concentration
b Defined as “susceptible”, “intermediate” or “resistant” based on the Clinical And 
Laboratory Standards Institute standards M100-S25
MIC (µg/mL)a S/I/Rb
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Athlin et  al. investigated the relationship between S. 
pneumoniae serotype and immunoglobulin (Ig) titer in 
community-acquired pneumococcal pneumonia patients 
[19]. Higher Ig titer ratios were observed in patients 
infected with serotypes with a thin capsule and medium/
high invasive potential (including 1, 7F, 4, 9 N, 9 V, and 
14) than in patients infected with serotypes with a thick 
capsule and low invasive potential (including 3, 6B, 19A, 
19F, and 23F). Low Ig titer ratios (<1) were predomi-
nantly found in patients infected with serotypes with a 
thick capsule. According to a report by Hennezel et  al. 
combination therapy with intravenous immunoglobulin 
(IVIG) and ampicillin was effective in a mouse model of 
invasive pneumonia caused by serotype 3 S. pneumoniae 
[20]. Based on these results, adding IVIG to the antibiotic 
therapy regimen may be an option in severe cases of IPD, 
such as the present case.
As the patient’s immunization status was unclear in 
the present case, the effectiveness of PPSV23 or PCV13 
against serotype 3 S. pneumoniae could not be evaluated. 
The case was further complicated by a history of hyper-
tension, laryngeal cancer, COPD, type 2 diabetes mellitus, 
and cerebral arteriovenous malformation hemorrhage. In 
addition, the patient’s nutritional status was not good, as 
indicated by the low serum albumin level. These factors 
possibly influenced the disease outcome. However, in 
severe cases caused by serotype 3 S. pneumoniae with a 
poor treatment response, as the present case, any avail-
able treatment measures such as the concomitant use of 
antibiotics and adding IVIG to the regimen should be 
considered. Raising awareness and promoting effective 
pneumococcal immunization would be other potential 
strategies to minimize the risk of serotype 3 infections.
We experienced a case of nosocomial pneumonia 
caused by mucoid serotype 3 S. pneumoniae with a ful-
minant course. The isolate was susceptible to all tested 
antibiotics other than erythromycin, but the case was not 
managed successfully. Serotype 3 isolates tend to have a 
thick capsule, and infected patients often have severe and 
refractory IPD. In particular, pneumonia due to serotype 
3, which tends to form mucoid colonies, may develop a 
wider pulmonary infiltrative shadow, a prolonged thera-
peutic or hospitalization period, and a poor outcome. 
Careful observation and intervention are required 
throughout the clinical course in such patients. Although 
the complicated background influenced the current 
patient’s outcome, additional use of other antibiotics 
or immunoglobulins could be considered as therapeu-
tic options when the pathogen is serotype 3 or another 
mucoid pneumococcus. In addition, effective and appro-
priate immunization for S. pneumoniae is an important 
public health measure to minimize the development of 
severe infections caused by serotype 3 strains.
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